Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 17;6:37201. doi: 10.1038/srep37201

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

WNT10B^IVS1 transcript levels showed a significative difference (p < 0.0001; Kruskal-Wallis test) between MRC (a), ELN (b) and NCNN (c) risk classes classification in a cohort of n = 125 AML patients (n = 70 intermediate and adverse-risk, n = 40 favorable-risk, n = 8 APL and n = 7 therapy-related). Comparative Mann-Whitney U-test showed a significative reduction of WNT10B^IVS1 levels in favorable versus adverse-intermediate risk patients (p < 0.001 for all three classification system). No statistical significance in WNT10B^IVS1 levels between intermediate and adverse-risk groups (MRC: Int vs Adv: p 0.4864; ELN: Int-1 vs Int-2 p 0.1500 and Int-1/2 vs Adv: p 0.6963; NCCN: Int vs Adv: p 0.9940). (d) Kruskal-Wallis test of WNT10B^IVS1 transcript distribution per WHO classes, showed a significative difference in WNT10B^IVS1 distribution (p < 0.0001). Comparative Mann-Whitney U-test: t-AML vs AML-RGA, AML-MDS and AML,NOS groups (p < 0.0005), AML-RGA vs t-AML, AML-MDS and AML,NOS groups (p < 0.003) and AML-MDS vs AML,NOS: p 0.5475. (e) Significative difference in WNT10B transcript levels between the distinct WHO splitted classes (p 0.0008; Kruskal-Wallis test), and comparative Mann-Whitney U-test endorsed a significative reduction in patients with therapy-related disease (p < 0.01). No statistical significance in WNT10B levels between all the other groups. (f) Significative difference in WNT10B^IVS1 transcript levels between the distinct WHO splitted classes (p < 0.0001; Kruskal-Wallis test). Comparative Mann-Whitney U-test confirmed a significative reduction of WNT10B^IVS1 levels in CBF-AML, APL, and therapy-related AML compared with patients with recurrent genetic abnormalities, NPM1/CEBPA mutation, MDS-related features, normal karyotype or other non-recurrent genetic number or structural abnormalities (p < 0.01). Data represent mean values ± s.d. (g) Graphical representation of patients cohort distribution (upper panel) and WNT10B/WNT10B^IVS1 mRNAs classification of AML patients (lower panel). (h) Consensus clustering 3D scatter plot of WNT10B and WNT10B^IVS1 transcript levels in the cohort of AML patients. Data represent mean values ± s.d. AML-RGA: AML with recurrent genetic abnormalities, AML-MDS: AML with myelodysplasia-related features, t-AML: therapy-related AML, AML,NOS: AML, not otherwise specified.